BioArctic (B9A) Stock Overview
Develops biological drugs for patients with central nervous system disorders in Sweden. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
B9A Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
BioArctic AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 27.64 |
| 52 Week High | SEK 34.96 |
| 52 Week Low | SEK 14.19 |
| Beta | -0.90 |
| 1 Month Change | -3.15% |
| 3 Month Change | -1.50% |
| 1 Year Change | 43.66% |
| 3 Year Change | 21.55% |
| 5 Year Change | 196.89% |
| Change since IPO | 253.77% |
Recent News & Updates
Recent updates
Shareholder Returns
| B9A | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -5.9% | 0.01% | -6.4% |
| 1Y | 43.7% | 2.1% | -1.7% |
Return vs Industry: B9A exceeded the German Biotechs industry which returned 2.1% over the past year.
Return vs Market: B9A exceeded the German Market which returned -1.7% over the past year.
Price Volatility
| B9A volatility | |
|---|---|
| B9A Average Weekly Movement | 9.3% |
| Biotechs Industry Average Movement | 9.6% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in DE Market | 14.4% |
| 10% least volatile stocks in DE Market | 2.6% |
Stable Share Price: B9A's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: B9A's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 131 | Gunilla Osswald | www.bioarctic.se |
BioArctic AB (publ) develops biological drugs for patients with central nervous system disorders in Sweden. It engages in the research and development of innovative biological drugs, such as antibodies that address high unmet medical needs. The company’s therapeutic areas encompass neurodegenerative disorders, such as Alzheimer’s disease, Parkinson’s disease, and other CNS diseases.
BioArctic AB (publ) Fundamentals Summary
| B9A fundamental statistics | |
|---|---|
| Market cap | €2.49b |
| Earnings (TTM) | €95.85m |
| Revenue (TTM) | €187.44m |
Is B9A overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| B9A income statement (TTM) | |
|---|---|
| Revenue | SEK 2.00b |
| Cost of Revenue | SEK 59.22m |
| Gross Profit | SEK 1.94b |
| Other Expenses | SEK 917.57m |
| Earnings | SEK 1.02b |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
Mar 09, 2026
| Earnings per share (EPS) | 11.52 |
| Gross Margin | 97.04% |
| Net Profit Margin | 51.14% |
| Debt/Equity Ratio | 0% |
How did B9A perform over the long term?
See historical performance and comparisonDividends
Does B9A pay a reliable dividends?
See B9A dividend history and benchmarks| BioArctic dividend dates | |
|---|---|
| Ex Dividend Date | May 29 2026 |
| Dividend Pay Date | Jun 04 2026 |
| Days until Ex dividend | 82 days |
| Days until Dividend pay date | 88 days |
Does B9A pay a reliable dividends?
See B9A dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/08 06:32 |
| End of Day Share Price | 2026/03/06 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
BioArctic AB (publ) is covered by 5 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kristofer Liljeberg-Svensson | DNB Carnegie |
| Rajan Sharma | Goldman Sachs |
| Viktor Sundberg | Nordea Markets |